Business Wire

SES

11.5.2023 08:51:31 CEST | Business Wire | Press release

Share
SES and TESAT to Develop Payload for Europe’s First Quantum Cryptography LEO Satellite System EAGLE-1

EAGLE-1 consortium lead SES announces a new key partner, TESAT, responsible for developing and integrating the Quantum Key Distribution (QKD) payload for the EAGLE-1 satellite. The SES and TESAT partnership is aimed at achieving the next key milestone in building and implementing Europe’s pioneering quantum secure communications initiative EAGLE-1. Supported by the European Space Agency (ESA) and the European Commission, EAGLE-1 is a quantum key system integrating both space and ground segments that will deliver secure transmission of encryption keys across geographically dispersed areas and connect EU’s national quantum communications infrastructures for truly sovereign networks.

Consortium member and Europe’s leading laser communication technology company TESAT will manufacture the QKD payload comprising the Scalable Optical Terminal SCOT80 to establish a secure optical link from space to ground, as well as the QKD module of the satellite.

The technology integrated into the EAGLE-1 system’s payload will include built-in redundancy and is specifically designed to be associated with the satellite communications and data transmission for such areas as government, telco operators, cloud providers and banking, to add guaranteed security of the cryptographic applications.

“EAGLE-1 is a project that will benefit the whole of Europe, and being able to work with the leading technology players in the market to co-develop it and together shape this innovative secure technology is a privilege to SES,” said Ruy Pinto, Chief technology Officer of SES. “The addition of the secure optical links and the actual QKD module brings us closer to implementation, testing and further scaling the technology, that can ultimately serve millions of users. This elevates secure communications to an entirely new level, supporting development of reliable pan-European quantum communications infrastructures.”

“We are delighted to be selected as payload prime by SES and looking forward to bring our expertise in integrating secure technologies, and a track record of almost 80,000 executed optical satellite links for the benefit of this highly-important and timely European project,” said Thomas Reinartz, CEO of TESAT. “The EAGLE-1 system allows for achieving synergies together with leading industry partners, SMEs and institutes, reducing time to service and to market for the quantum secure technologies and its future key users, such as governments and institutions, or banking sector. Together with our partners, we are looking forward to strengthen European collaboration at all levels, including SMEs and institutions and contributing to European sovereignty in space.”

About EAGLE-1

The EAGLE-1 project comprising satellite and ground infrastructure is developed by SES and its consortium of 20 European partners, and is co-funded by the ESA contribution of Germany, Luxembourg, Austria, Italy, the Netherlands, Switzerland, Belgium, and the Czech Republic under ARTES, as well as the European Commission through Horizon Europe.

Once launched in 2024, the EAGLE-1 satellite will complete three years of in-orbit mission. During the operational phase, the satellite will allow European Union governments and institutions as well as critical business sectors early access to long-distance QKD that would path the way towards an EU constellation enabling ultra-secure data transmissions.

Learn more about EAGLE-1 and SES-led consortium of European partners here.

Follow us on:

Twitter | Facebook | YouTube | LinkedIn | Instagram

Read our Blogs >
Visit the Media Gallery >

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over ~8,200 channels and has an unparalleled reach of 369 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com

About TESAT

TESAT is a world-leading manufacturer for satellite equipment. More than 1,100 employees, based in Backnang, Germany, develop, manufacture and distribute systems and equipment for satellite communications every day. The product range spans from the smallest space-specific components to modules, entire assemblies or payloads. As the world’s leading provider of in-orbit-verified optical communication terminals for data transmission via laser, TESAT has a focus on commercial and institutional space programs. Thanks to the deep understanding of the market needs, customer focus and technological innovation, TESAT offers products that contribute to sustainable development and security, for the people, for a better world. More information at www.tesat.de.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230510006052/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye